GlassScriptPhysician profile
David A Francis
NPI 1427062173
$1,767.47
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.23 · 2020: $584 · 2021: $511 · 2022: $320 · 2023: $252 · 2024: $24.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $182 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.16 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $518.47 | 2020-2024 | Mounjaro |
| Abbvie INC. | $149.04 | 2021-2023 | |
| Astellas Pharma US INC | $139.90 | 2020-2023 | |
| Novo Nordisk INC | $129.58 | 2019-2022 | |
| Pfizer INC. | $120.25 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.39 | 2020-2021 | |
| Glaxosmithkline, LLC. | $97.57 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $95.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.10 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.28 | 2022-2023 | |
| Abbott Laboratories | $46.42 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $43.25 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $40.01 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $29.64 | 2022-2023 | Contrave |
| Idorsia Pharmaceuticals US INC | $21.23 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.59 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.39 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.09 | 2021 | |
| Adlon Therapeutics L.P. | $13.69 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.08 | 2021 | |
| Amgen INC. | $11.86 | 2020 | |
| Ibsa Pharma INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.